Background Standardized MedDRA Queries (SMQs) are sets of terms determined by experts that are used to identify adverse events (AEs) related to different disease processes. Their use can be challenging because most SMQs have 50 to 100 preferred terms and AE databases can have many thousands of events. Aim The aim of this study is to develop a technique where AEs corresponding to preferred terms in SMQs may be easily detected. Methodology The method I developed uses the Table Join function of the JMP Ò software program to quickly and easily probe clinical trial AE databases. The SMQ Severe cutaneous adverse reactions was used as a probe in a mock AE dataset. Potentially confounding demographic or study-specific factors were evaluated by combining these datasets with the dataset containing the AEs identified with the SMQs. Results AEs were successfully detected in an AE database using the method described. Cases with potential confounding factors, such as concomitant medications, were identified. Conclusions The method developed allows for AEs to be found in clinical trial databases and evaluated using software programs that are readily available to clinical researchers.
Introduction
The Medical Dictionary for Regulatory Activities (Med-DRA) is a standardized international terminology that is used by regulatory authorities and the biopharmaceutical industry to share regulatory information about medical products. Standardised MedDRA Queries (SMQs) are tools developed to facilitate retrieval of MedDRA-coded data as a first step in investigating drug safety issues in pharmacovigilance and clinical development. SMQs are validated, pre-determined sets of MedDRA terms (typically preferred terms; PTs) related to specific medical conditions and there are currently almost 100 SMQs in production in MedDRA [1] . Screening with SMQs is particularly useful to evaluate adverse event (AE) databases for early signs of complex diseases, since a subject is often discontinued from a clinical trial before a disorder has fully developed. However, the analysis of AE databases with SMQs may be quite cumbersome, since the latter may contain dozens of PTs and hundreds of their subordinate lowest level terms (LLTs 
Adverse Event Dataset (AE)
The AE dataset was created in EXCEL so that the 100 mock subjects had 9 or 10 AEs each. Terms from Severe cutaneous adverse reactions (SMQ) were included in the first 14 subjects in this list to ensure and to measure assay sensitivity. Randomly chosen terms from other SMQs were included as the remaining 985 AE terms of the AE database.
Assembly of Datasets to Evaluate Other Patient Attributes
A dataset of concomitant medication (CM) was created by serially assigning Greek alphabet names as mock medications. Anatomical Therapeutic Class (ATC) classifications were assigned for demonstration purposes [3] . An asterisk (*) was added to two of the mock medication names to designate that they also were thought to cause severe cutaneous adverse reactions (SCARs), to illustrate the utility of this methodology.
Screening the Adverse Event Database for Specific SMQ Terms
The database to be screened (e.g. JMP 2) will be a subset of the AE database corresponding to those cases where a potential AE corresponding to the term in the SMQ has occurred.
Investigating Other Subject Attributes
JMP datasets with other attributes (e.g. concomitant medications, pharmacodynamics variables) can be added after the hybridization procedure by using the Table Join function, linking the datasets by the USUBJID variable. One can also join the other dataset to the AE_DM table before the SMQ hybridization procedure. In this study the CM dataset was joined to the DMAE_SMQ to form the dataset DMAESMQ_CM (Fig. 3) .
Results

SMQ Hybridization
Joining the AE to the SMQ dataset reduced the 999-row AE set to a 15-row dataset DMAE_SMQ, where each row had an event that was also included in the Severe cutaneous adverse reactions (SMQ) set of PTs. While 14 SCAR terms were included in the AE list to ensure there was a target for the SMQ to hybridize, PT Mouth ulceration was included in the AE dataset as a target for Systemic lupus erythematosus (SMQ). This term is also in Severe cutaneous adverse reactions (SMQ) and so it was also picked up with the hybridization technique.
Investigating Other Subject Attributes
Joining a CM dataset allowed for simulation of a realistic scenario where one would look for concomitant medications that could confound the association of the test drug and the AE (Fig. 3) . In this case, four subjects with SCARs (1001-004, -006, -012, and -016) were taking medications known to cause SCARs. For subjects 1001-004 and -006, the concomitant medication was taken after the AE, so it does not confound the relation of the test drug and the event. Subject 1001-012 took the concomitant medication prior to the event and subject 1001-014 took the concomitant medication on the same day as the event, so the events of these two subjects are confounded by the concomitant medications. 
Discussion
In this communication, a method is described for searching AE databases using SMQs to identify potential cases of interest. The method is reminiscent of RNA hybridization in that the SMQ terms function like a probe and the Table Join function acts like RNase, which eliminates the unhybridized terms leaving only those complementary to the probe. An illustrative example is provided to demonstrate the potential use and advantages of this technique. A limitation of this study is that it was based on a hypothetical, versus an actual clinical trial dataset; however, since the datasets created for this study were formatted in the same manner as actual datasets the utility of this methodology was not compromised.
Availability of Tools for SMQ Searches
While there are numerous statistical packages that allow linkage and partitioning of AE tables, there are few publications describing tools that may be used for SMQ searches. A program known as MAED (MedDRA-based Adverse Event Diagnostics) was developed and is used at the FDA to search for SMQ terms in adverse event databases [4] . This tool allows the user to specify test and reference treatments from an appropriate database and MedDRA levels from the AE database. Different statistical comparisons may be made between the test and control treatments. Numerator analyses may be performed on single-arm studies, such as open-label extensions. One may also drill down on results to identify patients identified with AEs corresponding to terms in SMQs. Directions for downloading and setting up the MAED program locally have been published [5] . Using SMQs to find terms is advantageous because the SMQ standardized term lists have been assembled though the collective efforts of the Council for International Organizations of Medical Sciences (CIOMS) and the MedDRA Maintenance and Support Services Organization. However, one may also augment the list of terms by adding or deleting PTs depending on their clinical relevance, although the resulting term list would then not be considered an SMQ [6] . Similarly, using this technique, one can easily merge terms of SMQs that describe a common clinical concept, as was done in the New Drug Application #22271 for Nesina (alogliptin), which combined the SMQs of Serious cutaneous adverse reactions, Angioedema, and Anaphylactic reactions to form a probe for systemic allergic reactions [7] . 
Useful Features of the SMQ Hybridization
Technique for Detecting Potential AEs using
SMQs in Databases
The detection of potential AEs with SMQs using the hybridization technique is convenient because it uses a readily available software program and is easy to perform. As demonstrated in the illustrative example, the ability to link other database tables to the resulting SMQ-matched terms allows the investigator to perform useful analyses. In the example in this study, the potential for concomitant medication to be considered a confounding factor was eliminated because the event onset preceded the administration of a concomitant medication. One may investigate other demographic factors, such as medical history and genetic data, or study events, such as laboratory and vital signs that may be associated with the AE.
A critical step in the identification of AEs with SMQs is the review and adjudication of cases to verify whether they actually had the medical condition represented by the SMQ used to retrieve the terms. Verification often includes evaluating laboratory values, prior and concomitant medications, other AEs from the subject's medical history, and whether the event preceded or followed potentially confounding factors. The hybridization technique allows the investigation of all of these basic data structures to support the safety analyses.
Conclusions
A method for detecting AEs that correspond to SMQ PTs is described. This method simplifies the difficult task of sorting through very large clinical trial databases during safety analyses. It can be done with software that is readily available and the methodology adapted so that the cases that are identified can be further evaluated using demographic and other clinical trial databases. Fig. 3 The SMQ hybridized AE Table joined to a Concomitant Medication Database. The highlighted rows are for cases where subjects were taking hypothetical drugs (marked with an asterisk) with a prior association with causing serious cutaneous adverse reactions. AE adverse event, CM concomitant medications, PT MedDRA preferred term, SMQ Standardized MedDRA Query, SMQ SCARS the dataset containing the Serious cutaneous adverse reactions (SMQ) preferred terms, USUBJID unique subject identification
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